Moderna stocks rebound on cancer focus

An advanced clinical trial has demonstrated that Moderna's treatment targeted at skin cancer, which combines a personalized vaccine based on messenger RNA technology with the drug Ketruda, shows positive results in reducing the risk of disease recurrence and spread. The study resulted in a 49% reduction in the risk of cancer recurrence or death compared to using Ketruda alone, with initial data indicating that the treatment may begin reaching patients next year after receiving "breakthrough therapy" designation. Meanwhile, the company's stock has risen by 158% in recent trading sessions, reaching its highest level in 26 months, amid expectations of sales reaching $3 billion by 2035 for melanoma treatment. These results reflect hope for expanding the use of messenger RNA technology in cancer therapies.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل